STOCK TITAN

Cv Sciences - CVSI STOCK NEWS

Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.

Overview

CV Sciences, Inc. is a comprehensive consumer wellness company that integrates science and nature to improve overall health and well-being. Specializing in nutraceuticals and plant-based foods, the company brings together scientifically-backed hemp extracts and natural ingredients across a diverse range of products. By leveraging deep research, clinical validations, and independent testing, CV Sciences positions itself as an informed and reliable entity in the health and wellness sector.

Core Business and Strategic Focus

The core mission of CV Sciences is to make healthy people healthier. The company’s operations span the development, manufacturing, and distribution of wellness products that cater to both human and pet consumers. Its business model is anchored on the production of hemp-based supplements and plant-derived food products that are sold through multiple channels including direct-to-consumer (B2C) and business-to-business (B2B) outlets. The product portfolio is carefully developed with an emphasis on science and quality, ensuring that each offering is supported by clinical research and complies with industry safety standards.

Product Portfolio and Innovation

CV Sciences offers an expansive range of product lines that exemplify its commitment to innovation and excellence. The +PlusCBD brand, a flagship in hemp extract supplements, has earned recognition for its research-backed approach and quality assurance through clinical studies and laboratory testing. Complementing this is the Cultured Foods brand, which provides a variety of 100% plant-based foods designed to meet the nutritional demands of vegan, gluten-free, and flexitarian consumers. The company has also recently expanded into pet wellness with specialized products designed to support joint health and calming effects for companion animals, an innovation that further extends its market reach.

Quality, Research, and Safety

A major component of CV Sciences' value proposition is its dedication to quality and safety. The company was one of the first to invest in generating scientific evidence required to obtain self-affirmed Generally Recognized as Safe (GRAS) status, particularly for its hemp extract supplements. Clinical research data and published studies support product benefits, ensuring that customers receive products that are not only natural but are scientifically validated for efficacy and safety. Independent laboratory tests and adherence to Good Manufacturing Practices (GMP) further solidify the company’s commitment to producing reliable and high-quality nutraceuticals.

Market Position and Competitive Landscape

Operating in the highly competitive consumer wellness and nutraceutical space, CV Sciences has distinguished itself through its diversified product portfolio and a robust focus on scientific research. Its offerings cater to a range of consumer needs, from natural wellness supplements to innovative pet care products, allowing the company to capture multiple market segments. The breadth of its product lines, combined with strategic measures such as mergers and acquisitions, positions CV Sciences as a resilient and adaptive participant in the natural products market. Detailed market insights and trend analyses reinforce its approach, ensuring that the company maintains a competitive edge in a rapidly evolving industry.

Global Presence and Operational Excellence

With primary offices and facilities strategically located in San Diego, California, and Warsaw, Poland, CV Sciences leverages a global operational framework to optimize production and distribution channels. The company’s strategic acquisitions, including Elevated Softgels and Extract Labs, enhance its manufacturing capabilities while providing operational flexibility and cost efficiencies. This global footprint underpins its long-standing commitment to excellence, ensuring consistent quality and timely delivery of state-of-the-art wellness products to customers worldwide.

Strategic Acquisitions and Integration

The proactive pursuit of strategic acquisitions bolsters CV Sciences’ operational capacity and enriches its product innovation pipeline. By integrating companies with complementary technologies and manufacturing strengths, such as Elevated Softgels and Extract Labs, the firm has expanded its ability to produce cost-effective and high-quality encapsulated supplements and tinctures. These acquisitions not only streamline the supply chain but also provide synergistic benefits that translate into enhanced market responsiveness and broader product offerings.

Commitment to Science and Consumer Wellness

At its core, CV Sciences is driven by a mission that combines scientific rigor with natural wellness. Every segment of its operation is designed to uphold the values of transparency, quality, and reliability. Whether through the development of hemp extract-based solutions, the diversification into cannabinoid-free wellness products under the +PlusHLTH brand, or the careful formulation of pet care products, the company consistently demonstrates its dedication to consumer well-being. This scientifically-oriented approach, coupled with a commitment to continuous innovation, underscores the company’s role as an authoritative source in the wellness industry.

In summary, CV Sciences offers a well-rounded, research-informed perspective on modern health and nutrition by providing a diverse array of nutraceutical and plant-based foods. Its strategic emphasis on scientific validation and operational excellence makes it a noteworthy name for anyone seeking comprehensive and quality-driven wellness solutions.

Rhea-AI Summary

CV Sciences, Inc. (OTCQB:CVSI) announced preliminary approval of a proposed settlement for a derivative lawsuit in Nevada, alleging breach of fiduciary duty. This lawsuit stemmed from events linked to a class action dismissed in July 2019. A settlement in principle was agreed upon in January 2022, with the U.S. District Court granting preliminary approval on February 7, 2023. A final hearing is scheduled for May 15, 2023. If approved, this settlement will resolve all claims without admitting wrongdoing by the company. Additionally, the settlement includes certain corporate reforms to be implemented within 60 days post-approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
-
Rhea-AI Summary

CV Sciences has announced the launch of a new 30-count bottle of its popular +PlusCBD™ Reserve Collection Softgels, set to be available from January 19, 2023. This product, which initially launched in August 2022 in a 60-count format, features a 10:1 ratio of CBD to THC, offering 12.5mg of CBD and 1.25mg of THC per softgel. The smaller bottle, priced at $37.99, aims to make the product more accessible for consumers, especially for those on a budget. CV Sciences emphasizes the product's benefits in addressing issues related to depression, stress, and anxiety, expanding its appeal to both experienced users and newcomers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

CV Sciences, Inc. (CVSI) reported third-quarter 2022 revenue of $3.8 million, down 27% from $5.1 million in Q3 2021. Gross margin decreased to 41.6% from 46.2% year-over-year. Operating loss improved to $0.9 million, significantly reduced from $3.0 million in the same quarter last year. Adjusted EBITDA was negative $1.2 million, an improvement from negative $2.7 million. The company launched new products and maintained its position as the top-selling hemp extract brand.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

CV Sciences, Inc. (OTCQB:CVSI) will release its third-quarter financial results for the period ending September 30, 2022, on November 14, 2022, before the market opens. A conference call will be held the same day at 7:00 a.m. PT, accessible via phone or webcast. The company, known for its PlusCBD™ products, operates in both consumer product manufacturing and drug development. CV Sciences adheres to strict manufacturing practices and has achieved self-affirmed GRAS status for its products, supported by clinical research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

CV Sciences, Inc. (OTCQB: CVSI) announced preliminary approval of a proposed settlement regarding six shareholder derivative lawsuits related to allegations of misleading investors concerning patent protection for CVSI-007. The lawsuits arose from a tweet by Citron Research on August 20, 2018. The proposed settlement will involve payment of $275,000 in attorneys' fees, expected to be covered by insurance. The final approval is pending a court hearing on November 14, 2022. All claims will be resolved without admission of wrongdoing by the Company or defendants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

CV Sciences, Inc. (OTCQB:CVSI) announced the complete retirement of its convertible debt, strengthening its balance sheet and eliminating the dilutive impact on shareholders. CEO Joseph Dowling emphasized that this move will alleviate downward pressure on CVSI stock, allowing the company to focus on enhancing shareholder value and expanding its PlusCBD™ branded product line. This strategic decision was detailed in a Current Report on Form 8-K filed with the SEC on August 25, 2022. For more information, visit www.cvsciences.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
100%
Tags
none
Rhea-AI Summary

CV Sciences reported its first-quarter 2022 financial results, recording revenue of $4.4 million, down 8% from $4.8 million in Q1 2021. The gross margin dropped to 26.0% compared to 32.4% in Q4 2021. However, the total cash balance increased to $2.4 million from $1.4 million at year-end 2021. The company launched several new OTC pain relief products and claimed $2.0 million in employee retention credits. Although sales volume increased 3%, it was offset by higher discounts, resulting in an operating loss reduction to $1.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

CV Sciences (OTCQB:CVSI) will release its first quarter financial results on May 16, 2022, before market open. The company, known for manufacturing hemp CBD products, will hold a conference call at 7:00 a.m. PT (10:00 a.m. ET) to discuss the results. Investors can participate via phone or access a webcast available on their Investor Relations website.

CV Sciences operates in two segments: consumer products and drug development, with PlusCBD™ being a leading brand in the hemp-derived CBD market. The company adheres to Good Manufacturing Practices and supports product efficacy through clinical research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

CV Sciences reported a 2021 revenue of $20.0 million, down 18% from $24.4 million in 2020. The gross margin decreased to 43.0% from 45.1%, with a total cash balance of $1.4 million, down from $4.5 million. Despite these challenges, retail distribution grew to over 8,400 stores and operating losses reduced to $18.4 million. CV Sciences introduced several new products, including the clinical strength ProCBD™ line, aiming for future growth amid competitive pressures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.53%
Tags
Rhea-AI Summary

CV Sciences, a leading manufacturer of hemp CBD products, announced it will disclose its financial results for Q4 and full year 2021 on March 31, 2022, after market close. A conference call will take place at 1:30 p.m. PT (4:30 p.m. ET) on the same day, available via webcast on their Investor Relations website. Investors can listen live or access a replay through specific phone numbers provided. The company operates in two segments: consumer products for dietary supplements and drug development focused on CBD therapeutics, with products sold in over 8,400 retail locations across the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Cv Sciences (CVSI)?

The current stock price of Cv Sciences (CVSI) is $0.0325 as of April 8, 2025.

What is the market cap of Cv Sciences (CVSI)?

The market cap of Cv Sciences (CVSI) is approximately 5.7M.

What core business does CV Sciences focus on?

CV Sciences specializes in consumer wellness products by integrating science and natural ingredients. Its operations include the development and distribution of hemp extract supplements, plant-based foods, and pet wellness products.

How does CV Sciences ensure product quality and safety?

The company adheres to stringent quality standards including GMP-certification and independent laboratory testing. Its products are supported by clinical research and published studies, ensuring safety and efficacy.

What distinguishes the +PlusCBD brand?

The +PlusCBD brand is known for its science-backed approach, clinical research support, and self-affirmed GRAS status. It is recognized as a top-selling hemp extract supplement within the natural products market.

What role do strategic acquisitions play in CV Sciences' growth?

Strategic acquisitions like Elevated Softgels and Extract Labs enhance the company’s manufacturing capabilities and operational flexibility. These moves allow CV Sciences to in-source production and expand its product portfolio cost-effectively.

How does CV Sciences cater to the pet wellness market?

CV Sciences has developed specialized pet products, such as CBD-infused chews for joint and calming health, which are supported by rigorous research and validated by safety studies. These offerings extend the company’s commitment to consumer well-being to pet care.

What is CV Sciences' approach to innovation?

Innovation at CV Sciences is driven by a commitment to scientific research and the integration of natural ingredients. The company continuously develops new products and explores strategic opportunities to enhance its portfolio and market reach.

Which sales channels does CV Sciences use to reach its customers?

CV Sciences employs a diverse sales strategy that includes both B2B and B2C channels. This allows the company to effectively distribute its wellness products through selected retail locations as well as direct consumer platforms.

How does the company maintain its global operational efficiency?

With key facilities in San Diego and Warsaw, CV Sciences leverages a global operational framework. Strategic acquisitions and a focus on manufacturing excellence ensure that the company maintains high standards in production and distribution.
Cv Sciences

OTC:CVSI

CVSI Rankings

CVSI Stock Data

5.71M
184.23M
0.02%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
San Diego